London: With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the chronic kidney disease (CKD) market is forecast to grow at a compound annual growth rate (CAGR) of 19.6 per cent from $2.2 billion in 2023 to $13.5 billion in 2033 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan), according to GlobalData.

GlobalData’s latest report ‘Chronic Kidney Disease: Seven-Market Drug Forecast and Market Analysis‘, reveals that the US will contribute the most to the growth of the CKD market due to the higher prevalence of CKD in this market, as well as the substantially higher cost of prescription medications in the country compared with Europe and Japan.

Kajal Jaddoo, Senior Pharma Analyst, GlobalData, commented, The pressure on pharmaceutical companies to be more innovative with their therapies and tackle unmet needs is increasing. Companies are approaching the CKD market with the strategies of optimising treatment safety and compliance, as well as developing novel drug classes. The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has remained relatively consistent, and the use of sodium-glucose transporter 2 inhibitors has become well established for CKD.”

Over the forecast period of 2023–33, GlobalData expects the launches of promising pipeline drugs REACT (rilparencel), Ozempic (semaglutide), zibotentan + dapagliflozin combination, and balcinrenone + dapagliflozin combination to increase market size and further promote growth.

Jaddoo concluded, “It will be easier for new drug entrants to capture CKD market share if they offer a novel mechanism of action or help to improve compliance. The key opinion leaders interviewed by GlobalData hold mixed views on adding another drug on top of their patients’ complex treatment regimens.

Overall, nephrologists surveyed by GlobalData have indicated that the pipeline for CKD is somewhat promising, but a significant improvement in efficacy would have to be demonstrated by any therapy for it to become either a replacement or add-on to the existing therapies.”

  • Published On Jun 26, 2024 at 05:20 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App